18F-KS1:新型抗坏血酸衍生物用于肿瘤氧化应激成像的初步生物学评价
本研究设计并合成了一种新型抗坏血酸衍生物KS1,并用18F标记获得18F-KS1,在头颈鳞癌和前列腺癌细胞及前列腺癌荷瘤小鼠中评估其靶向活性氧(ROS)的能力。结果显示18F-KS1放射化学纯度>94%、比活度约100 GBq/μmol,细胞摄取可被非放射性KS1和超氧化物歧化酶(SOD)阻断,体内肿瘤摄取可被非标记KS1显著阻断(三倍),肿瘤/肌肉比值高。结论认为18F-KS1在体外和体内均初步支持用于肿瘤ROS PET成像。
要点
- 18F-KS1放射化学纯度>94%,比活度约100 GBq/μmol(EOS)。
- 细胞摄取可被非放射性KS1和SOD显著阻断,体现特异性。
- 荷瘤小鼠中肿瘤摄取可被非标记KS1阻断约三倍,肿瘤/肌肉比值高。
核心结论
- 18F-KS1在体外和体内均获得初步强支持,可用于肿瘤ROS的PET成像。
研究设计与样本
- 设计、合成并表征新型抗坏血酸衍生物KS1,并用18F进行亲核取代反应标记。
- 在两种ROS水平不同的头颈鳞癌细胞中用基于MitoSOX的体外ROS实验评估KS1,以抗坏血酸为参照标准。
- 在头颈鳞癌和前列腺癌细胞中测定18F-KS1的体外反应性与特异性。
- 在前列腺癌荷瘤小鼠中进行microPET显像和标准生物分布研究,并用非放射性KS1进行阻断实验。
主要发现
- MitoSOX实验显示KS1和抗坏血酸浓度增加与反应性升高呈良好相关性,且高ROS的SCC-61细胞反应性高于低ROS的rSCC-61细胞。
- 18F-KS1在两类癌细胞中摄取均高,且可被非放射性KS1和ROS阻断剂SOD显著阻断。
- 缺氧条件下前列腺癌细胞中18F-KS1摄取增加。
- 前列腺癌荷瘤小鼠中18F-KS1特异性结合肿瘤,预注射非标记KS1可显著阻断(三倍)。
- 生物分布研究显示肿瘤/肌肉(靶/非靶)比值高。
关键数值与推荐
- 18F-KS1放射化学纯度>94%,合成结束时比活度约100 GBq/μmol。
- 肿瘤摄取可被预注射非标记KS1显著阻断,阻断幅度为三倍。
临床怎么用
- 18F-KS1有望作为PET探针无创定量肿瘤ROS水平,辅助开发新疗法和按肿瘤ROS状态对患者进行分层。
- 该探针的实时ROS评估可能提升针对受ROS影响的肿瘤、神经退行性疾病和心血管疾病的精准医学方法。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reactive oxygen species (ROS)-induced oxidative stress damages many cellular components such as fatty acids, DNA, and proteins. This damage is implicated in many disease pathologies including cancer and neurodegenerative and cardiovascular diseases. Antioxidants like ascorbate (vitamin C, ascorbic acid) have been shown to protect against the deleterious effects of oxidative stress in patients with cancer. In contrast, other data indicate potential tumor-promoting activity of antioxidants, demonstrating a potential temporal benefit of ROS. However, quantifying real-time tumor ROS is currently not feasible, since there is no way to directly probe global tumor ROS. In order to study this ROS-induced damage and design novel therapeutics to prevent its sequelae, the quantitative nature of positron emission tomography (PET) can be harnessed to measure in vivo concentrations of ROS. Therefore, our goal is to develop a novel translational ascorbate-based probe to image ROS in cancer in vivo using noninvasive PET imaging of tumor tissue. The real-time evaluations of ROS state can prove critical in developing new therapies and stratifying patients to therapies that are affected by tumor ROS. METHODS: We designed, synthesized, and characterized a novel ascorbate derivative (E)-5-(2-chloroethylidene)-3-((4-(2-fluoroethoxy)benzyl)oxy)-4-hydroxyfuran-2(5H)-one (KS1). We used KS1 in an in vitro ROS MitoSOX-based assay in two different head and neck squamous cancer cells (HNSCC) that express different ROS levels, with ascorbate as reference standard. We radiolabeled 18F-KS1 following 18F-based nucleophilic substitution reactions and determined in vitro reactivity and specificity of 18F-KS1 in HNSCC and prostate cancer (PCa) cells. MicroPET imaging and standard biodistribution studies of 18F-KS1 were performed in mice bearing PCa cells. To further demonstrate specificity, we performed microPET blocking experiments using nonradioactive KS1 as a blocker. RESULTS: KS1 was synthesized and characterized using 1H NMR spectra. MitoSOX assay demonstrated good correlations between increasing concentrations of KS1 and ascorbate and increased reactivity in SCC-61 cells (with high ROS levels) versus rSCC-61cells (with low ROS levels). 18F-KS1 was radiolabeled with high radiochemical purity (> 94%) and specific activity (~ 100 GBq/μmol) at end of synthesis (EOS). Cell uptake of 18F-KS1 was high in both types of cancer cells, and the uptake was significantly blocked by nonradioactive KS1, and the ROS blocker, superoxide dismutase (SOD) demonstrating specificity. Furthermore, 18F-KS1 uptake was increased in PCa cells under hypoxic conditions, which have been shown to generate high ROS. Initial in vivo tumor uptake studies in PCa tumor-bearing mice demonstrated that 18F-KS1 specifically bound to tumor, which was significantly blocked (threefold) by pre-injecting unlabeled KS1. Furthermore, biodistribution studies in the same tumor-bearing mice showed high tumor to muscle (target to nontarget) ratios. CONCLUSION: This work demonstrates the strong preliminary support of 18F-KS1, both in vitro and in vivo for imaging ROS in cancer. If successful, this work will provide a new paradigm to directly probe real-time oxidative stress levels in vivo. Our work could enhance precision medicine approaches to treat cancer, as well as neurodegenerative and cardiovascular diseases affected by ROS.
引用
- Solingapuram Sai KK, Bashetti N, Chen X, et al. Initial biological evaluations of 18F-KS1, a novel ascorbate derivative to image oxidative stress in cancer. EJNMMI Res. 2019. PMID: 31101996. doi:10.1186/s13550-019-0513-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。